The FDA added six more therapies to its Commissioner’s National Priority Voucher (CNPV) program, expanding a pilot designed to accelerate review of drugs deemed in the national interest. The second tranche includes high‑profile obesity candidates such as Eli Lilly’s orforglipron and an oral Wegovy application from Novo Nordisk, positioning those dossiers for dramatically shortened review timelines. The vouchers — part of an administration push tied to pricing deals with major GLP‑1 makers — can compress standard 10–12 month reviews to decisions within weeks or months. The agency said selected sponsors will receive priority review; officials framed the program as a lever to speed access for therapies aligned with U.S. health priorities. Industry groups flagged trade‑offs: faster review can benefit patients but also raises questions about resource strain at regulators and potential market distortions if voucher winners tie to specific commercial agreements. Drugmakers and investors will watch which assets receive slots next and how the expedited pathway alters launch timetables.